WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2011140170) IMMUNOTHERAPY USING REDIRECTED ALLOGENEIC CELLS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2011/140170    International Application No.:    PCT/US2011/035104
Publication Date: 10.11.2011 International Filing Date: 04.05.2011
IPC:
C12N 5/02 (2006.01), C12N 15/11 (2006.01)
Applicants: YEDA RESEARCH AND DEVELOPMENT CO. LTD. [IL/IL]; The Weizmann Institute of Science P.O. Box 95 76100 Rehovot (IL) (For All Designated States Except US).
ESHHAR, Zelig [IL/IL]; (IL) (For US Only).
MARCUS, Assaf [IL/IL]; (IL) (For US Only).
WAKS, Tova [IL/IL]; (IL) (For US Only).
GERAGHTY, Erin [US/US]; (US) (SD only)
Inventors: ESHHAR, Zelig; (IL).
MARCUS, Assaf; (IL).
WAKS, Tova; (IL)
Agent: BROWDY, Roger, L.; Browdy and Neimark, P.L.L.C. Suite 1100 1625 K Street, N.W. Washington, District of Columbia 20006 (US)
Priority Data:
61/331,325 04.05.2010 US
Title (EN) IMMUNOTHERAPY USING REDIRECTED ALLOGENEIC CELLS
(FR) IMMUNOTHÉRAPIE À BASE DE CELLULES ALLOGÉNIQUES REDIRIGÉES
Abstract: front page image
(EN)A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.
(FR)L'invention concerne une méthode de traitement d'une maladie, tel qu'un cancer, par l'administration à un patient nécessitant un tel traitement d'une quantité efficace de lymphocytes T allogéniques avec un temps réduit de récepteur chimère non restreint au CMH après lymphodéplétion partielle. Cette méthode consiste également à administrer au moins un agent qui retarde la sortie des lymphocytes T allogéniques des ganglions lymphatiques du patient pendant le transfert adoptif des lymphocytes T allogéniques au patient, par piégeage des lymphocytes T dans les ganglions lymphatiques.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)